Cassava Looks to Extend Breakneck Rally on Alzheimer’s Data
- Alzheimer’s results expected at industry meeting on July 29
- Stock closes Tuesday at highest level in more than 20 years
This article is for subscribers only.
Another double-digit share price rally could be in store for Cassava Sciences Inc. over the next month, as the biotech vies with retail trading favorites AMC Entertainment Holdings Inc. and GameStop Corp. to be the year’s top-performing stock in the Russell 3000.
In the run-up to the big reveal from a mid-stage study, the 23-year old drug developer has sprinted more than 1,700% this year. On July 29, Cassava is expected to present safety and cognition data from about 50 people with mild or moderate Alzheimer’s disease after they completed nine months of treatment with the experimental medicine, simufilam.